To better understand the effect of a new split variant of human asialoglycoprotein receptor (ASGPR H1b) on ASGPR ligands’ binding ability, we established a functional cell line which expresses ASGPR.The full lengths ...To better understand the effect of a new split variant of human asialoglycoprotein receptor (ASGPR H1b) on ASGPR ligands’ binding ability, we established a functional cell line which expresses ASGPR.The full lengths of ASGPRH1a and H2c fragments from human liver were amplified by reverse transcript PCR (RT-PCR) and inserted into eukaryotic expression vector pIRES2EFP, pCDNA3.1 (Zeo+) respectively.The recombinants were cotransfected into HeLa cells.After selection by using Neocin and Zeocin, a stably transfected cell line was established, which was designated 4-1-6.The transcription and expression of ASGPRH1a and H2c in 4-1-6 were confirmed by RT-PCR, Western blotting and immunofluorescence.The endocytosis function of the artificial "ASGPR" on the surface of 4-1-6 was tested by FACS.It was found that the cell line 4-1-6 could bind ASGPR natural ligand molecular asialo-orosomucoid (ASOR).After the eukaryotic plasmid H1b/pCDNA3.1 (neo) was transfected into cell line 4-1-6, H1b did not down-regulate the ligand binding ability of ASGPR.The eukaryotic expression plasmid H1b/pcDNA3.1 (neo) and H2c/pcDNA3.1 (neo) were co-transfected transiently into Hela cell.Neither single H1b nor H1b and H2c could bind ASOR.In conclusion, a functional cell line of human asialoglycoprotein receptor (ASGPR) which expresses both H1a and H2c stably was established.The new split variant H1b has no effect on ASGPR binding to ASOR.ASGPRH1b alone can’t bind to ASOR, it yet can’t form functional complex with ASGPRH2c.展开更多
目的构建含人/鼠嵌合粘附分子CD44拼接变异体6(chimeric human and mouse CD44 splice variant 6,h/mCD44v6)基因真核表达质粒pcDNA3.1(+)-h/mCD44v6,并进行表达。方法通过PCR扩增h/mCD44v6的全基因cDNA,将扩增的cDNA克隆至PGM-Teasy,...目的构建含人/鼠嵌合粘附分子CD44拼接变异体6(chimeric human and mouse CD44 splice variant 6,h/mCD44v6)基因真核表达质粒pcDNA3.1(+)-h/mCD44v6,并进行表达。方法通过PCR扩增h/mCD44v6的全基因cDNA,将扩增的cDNA克隆至PGM-Teasy,测序后插入pcD-NA3.1(+)真核表达质粒,构建重组真核表达质粒pcD-NA3.1(+)-h/mCD44v6,经限制内切酶酶切分析及测序鉴定后,用脂质体转染B16细胞,通过RT-PCR扩增出B16/pcDNA3.1(+)-h/mCD44v6细胞株中h/mCD44v6全段基因cDNA。结果经4轮PCR,成功扩增出h/mCD44v6的cD-NA全长基因,成功构建了真核表达质粒pcDNA3.1(+)-h/mCD44v6,通过RT-PCR方法证实该质粒能在B16真核细胞中正确表达;建立了稳定的细胞株B16/pcDNA3.1(+)-h/mCD44v6。结论成功克隆和构建了h/mCD44v6的真核表达质粒pcDNA3.1(+)-h/mCD44v6,为进一步研究h/mCD44v6的新功能和免疫治疗奠定了基础。展开更多
基金supported by grants from the National Major Science and Technology Special Project for Infectious Diseases of China (No.2008ZX10002-011)National High Technology Research and Development of China (Program 863) (No.2006AA02Z128)the National Natural Science Foundation of China (Nos.30700701,30571646)
文摘To better understand the effect of a new split variant of human asialoglycoprotein receptor (ASGPR H1b) on ASGPR ligands’ binding ability, we established a functional cell line which expresses ASGPR.The full lengths of ASGPRH1a and H2c fragments from human liver were amplified by reverse transcript PCR (RT-PCR) and inserted into eukaryotic expression vector pIRES2EFP, pCDNA3.1 (Zeo+) respectively.The recombinants were cotransfected into HeLa cells.After selection by using Neocin and Zeocin, a stably transfected cell line was established, which was designated 4-1-6.The transcription and expression of ASGPRH1a and H2c in 4-1-6 were confirmed by RT-PCR, Western blotting and immunofluorescence.The endocytosis function of the artificial "ASGPR" on the surface of 4-1-6 was tested by FACS.It was found that the cell line 4-1-6 could bind ASGPR natural ligand molecular asialo-orosomucoid (ASOR).After the eukaryotic plasmid H1b/pCDNA3.1 (neo) was transfected into cell line 4-1-6, H1b did not down-regulate the ligand binding ability of ASGPR.The eukaryotic expression plasmid H1b/pcDNA3.1 (neo) and H2c/pcDNA3.1 (neo) were co-transfected transiently into Hela cell.Neither single H1b nor H1b and H2c could bind ASOR.In conclusion, a functional cell line of human asialoglycoprotein receptor (ASGPR) which expresses both H1a and H2c stably was established.The new split variant H1b has no effect on ASGPR binding to ASOR.ASGPRH1b alone can’t bind to ASOR, it yet can’t form functional complex with ASGPRH2c.
文摘目的构建含人/鼠嵌合粘附分子CD44拼接变异体6(chimeric human and mouse CD44 splice variant 6,h/mCD44v6)基因真核表达质粒pcDNA3.1(+)-h/mCD44v6,并进行表达。方法通过PCR扩增h/mCD44v6的全基因cDNA,将扩增的cDNA克隆至PGM-Teasy,测序后插入pcD-NA3.1(+)真核表达质粒,构建重组真核表达质粒pcD-NA3.1(+)-h/mCD44v6,经限制内切酶酶切分析及测序鉴定后,用脂质体转染B16细胞,通过RT-PCR扩增出B16/pcDNA3.1(+)-h/mCD44v6细胞株中h/mCD44v6全段基因cDNA。结果经4轮PCR,成功扩增出h/mCD44v6的cD-NA全长基因,成功构建了真核表达质粒pcDNA3.1(+)-h/mCD44v6,通过RT-PCR方法证实该质粒能在B16真核细胞中正确表达;建立了稳定的细胞株B16/pcDNA3.1(+)-h/mCD44v6。结论成功克隆和构建了h/mCD44v6的真核表达质粒pcDNA3.1(+)-h/mCD44v6,为进一步研究h/mCD44v6的新功能和免疫治疗奠定了基础。
